Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Int Immunopharmacol ; 79: 106051, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31863923

RESUMO

OBJECTIVE: Statins have immunomodulatory potential in autoimmune diseases but had not been studied as a disease-modifying agent in inflammatory myopathies. The objective of this study is to assess the effect of simvastatin in an experimental model of autoimmune myositis in mice on muscle strength and histopathology. METHODS: Four groups of mice (n = 5 per group) were selected for experimentally induced myositis. Mice were immunized with 1.5 mg myosin in complete Freund's adjuvant weekly for two times and injected with 500 ng pertussis toxin twice immediately after each immunization. From day 1 before immunization to 10 days after the last immunization, mice were treated with oral simvastatin (10 or 20 or 40 mg/kg) diluted in DMSO. The control group mice were injected with complete Freund's adjuvant weekly for two times and did not receive treatment. Non-immunized mice (n = 5 per group) were treated either with simvastatin (5 mg/kg or 20 mg/kg or 40 mg/kg of simvastatin diluted in DMSO) or with DMSO. RESULTS: Inflammation was observed in myositis groups with positive myositis-specific antibodies. Muscle strength dropped significantly after immunization. Immunized simvastatin 20 mg/kg treated group had significantly higher muscle strength versus non-treated myositis mice and versus other simvastatin doses. Besides, a trend toward higher serum Th17 percentage population was found in immunized non-treated mice, versus immunized simvastatin- treated mice, without significant difference. CONCLUSION: Simvastatin at 20 mg/kg decreases the severity of myositis in experimental autoimmune myositis and is a candidate of being a disease-modifying agent in inflammatory myopathies.


Assuntos
Anti-Inflamatórios/uso terapêutico , Inflamação/tratamento farmacológico , Doença Autoimune do Sistema Nervoso Experimental/tratamento farmacológico , Sinvastatina/uso terapêutico , Células Th17/imunologia , Animais , Autoanticorpos/sangue , Autoantígenos/imunologia , Feminino , Humanos , Camundongos , Camundongos Endogâmicos BALB C , Força Muscular/efeitos dos fármacos , Miosinas/imunologia
2.
Ann Dermatol Venereol ; 142(3): 189-92, 2015 Mar.
Artigo em Francês | MEDLINE | ID: mdl-25620556

RESUMO

BACKGROUND: Antisynthetase syndrome is characterized by the presence of interstitial lung disease, inflammatory myopathy, joint disease, Raynaud's phenomenon and characteristic skin lesions of the hands known as "mechanic's hands" associated with the presence of serum antibody to aminoacyl transfer-RNA synthetases. We report the case of a patient in whom cutaneous relapse consistently preceded CT evidence of pulmonary fibrosis flare-up. PATIENT AND METHODS: A 56-year-old patient consulted for recent exertional dyspnoea and dry cough. Clinical examination showed the skin of the tips and edges of the fingers to be thickened, hyperkeratotic and fissured. High-resolution computed tomography thoracic scans revealed interstitial lung lesions affecting both lower lobes. Lab tests showed elevated serum creatine kinase and positivity for anti-Jo-1 antibodies. Response to treatment with corticosteroids and cyclophosphamide was marked by an improvement in symptoms and regression of radiological anomalies together with disappearance of cutaneous signs. Nine months later, after changeover from cyclophosphamide to mycophenolate mofetil, cutaneous relapse and flare of interstitial lung disease were observed. A second course of cyclophosphamide followed by azathioprine resulted in regression of the cutaneous and pulmonary lesions. CONCLUSION: Mechanic's hands may be considered a marker of visceral involvement and should be sought in any instance of suspected antisynthetase syndrome flare-up.


Assuntos
Dermatoses da Mão/etiologia , Miosite/complicações , Humanos , Masculino , Pessoa de Meia-Idade , Miosite/diagnóstico
3.
Int Sch Res Notices ; 2015: 639796, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-27347535

RESUMO

Background. Food allergy (FA) is an important health problem in Western countries but there is limited data on the prevalence of food allergy in the Middle East. The main objective of our study is to assess the prevalence of self-reported food allergy in Lebanon. Methods. The survey was conducted by Telephone Calls questionnaire through random selection of landline phone numbers from the white pages all over Lebanon. A study questionnaire addressing the main objectives of the study was filled during the telephone call conversation. Results. Food allergy prevalence is estimated to be 4.1% in infants and children and 3.2% in adults. 65% of patients suffering from food allergy are females and 35% are males. Skin reactions are the most common symptoms among food allergy sufferers, reported in 86% of the cases. Signs of anaphylaxis appeared in 10.8% of cases. Fruits were the most common allergens at 35%, followed by eggs (19%) and nuts (16%). Cow's milk and spices ranked fourth (14%). Only half of food allergy sufferers sought medical advice. Allergists, dermatologists, gastroenterologists, or GPs (general practitioners) were consulted. Blood testing for specific IgE was the main diagnostic tool used by physicians. Conclusion. This is a pilot study of self-reported food allergy prevalence in Lebanon based on telephone survey. General prevalence is estimated to be 4.1% in infants and children and 3.2% in adults. Our study may improve awareness for proper diagnosis, food elimination, and acquisition of epinephrine autoinjectors in this part of the world.

4.
Rev Med Interne ; 33(7): 396-400, 2012 Jul.
Artigo em Francês | MEDLINE | ID: mdl-22703728

RESUMO

INTRODUCTION: Exophthalmia can be associated with several disorders. Although unusual, a carotid-cavernous fistula should be ruled out systematically as it may be associated with severe complications. CASE REPORTS: We report three cases associated with both types of carotid-cavernous fistula that highlight the clinical presentation and diagnostic process. CONCLUSION: A carotid-cavernous fistula should be systematically ruled out in patients with a uni- or bilateral exophthalmia. Careful examination with auscultation of the ocular globe contributes greatly to the diagnosis that may be confirmed by MRI or arteriography.


Assuntos
Fístula Arteriovenosa/diagnóstico , Artérias Carótidas/diagnóstico por imagem , Fístula Carótido-Cavernosa/diagnóstico , Seio Cavernoso/diagnóstico por imagem , Exoftalmia/etiologia , Idoso , Idoso de 80 Anos ou mais , Fístula Arteriovenosa/diagnóstico por imagem , Fístula Arteriovenosa/terapia , Fístula Carótido-Cavernosa/complicações , Fístula Carótido-Cavernosa/diagnóstico por imagem , Feminino , Humanos , Pessoa de Meia-Idade , Radiografia
8.
Rev Med Interne ; 32(11): e114-5, 2011 Nov.
Artigo em Francês | MEDLINE | ID: mdl-21145142

RESUMO

Many neurologic and psychiatric manifestations have been associated with systemic lupus erythematosus. Narcolepsy, currently hypothesized as related to an autoimmune process, has been rarely associated with systemic lupus erythematosus. We report a 36-year-old woman who presented with narcolepsy and who subsequently developed systemic lupus erythematosus. Excessive daytime sleepiness resolved after the administration of four intravenous bolus of cyclophosphamide and methylprednisolone followed by maintenance therapy with hydroxychloroquine, aspirine and prednisone. Narcolepsy should be included in the neuropsychiatric manifestations of systemic lupus erythematosus and it may have a parallel clinical course to the activity of the lupus.


Assuntos
Lúpus Eritematoso Sistêmico/complicações , Narcolepsia/complicações , Adulto , Aspirina/administração & dosagem , Ciclofosfamida/administração & dosagem , Quimioterapia Combinada , Feminino , Humanos , Hidroxicloroquina/administração & dosagem , Lúpus Eritematoso Sistêmico/diagnóstico , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Quimioterapia de Manutenção , Metilprednisolona/administração & dosagem , Narcolepsia/diagnóstico , Narcolepsia/tratamento farmacológico , Prednisona/administração & dosagem
9.
Rev Med Interne ; 30(9): 803-5, 2009 Sep.
Artigo em Francês | MEDLINE | ID: mdl-19674818

RESUMO

There are several possible pathophysiological links between the development of pulmonary hypertension and myelofibrosis with myeloid metaplasia. We report a woman with myelofibrosis and myeloid metaplasia who presented with dyspnea and massive, painful splenomegaly. Right heart catheterization evidenced pulmonary hypertension. Her management consisted of splenic irradiation associated to sildenafil. Dyspnea in patients with myelofibrosis and myeloid metaplasia can be secondary to pulmonary hypertension and conversely the differential diagnosis of pulmonary hypertension should include a myeloproliferative syndrome.


Assuntos
Dispneia/etiologia , Hipertensão Pulmonar/complicações , Mielofibrose Primária/complicações , Esplenopatias/complicações , Anticoagulantes/administração & dosagem , Anticoagulantes/uso terapêutico , Cateterismo Cardíaco , Diagnóstico Diferencial , Diuréticos/administração & dosagem , Diuréticos/uso terapêutico , Quimioterapia Combinada , Ecocardiografia Doppler , Eletrocardiografia , Feminino , Fibrinolíticos/administração & dosagem , Fibrinolíticos/uso terapêutico , Furosemida/administração & dosagem , Furosemida/uso terapêutico , Heparina de Baixo Peso Molecular/administração & dosagem , Heparina de Baixo Peso Molecular/uso terapêutico , Humanos , Hipertensão Pulmonar/diagnóstico , Hipertensão Pulmonar/tratamento farmacológico , Pessoa de Meia-Idade , Transtornos Mieloproliferativos/diagnóstico , Cuidados Paliativos , Inibidores de Fosfodiesterase/administração & dosagem , Inibidores de Fosfodiesterase/uso terapêutico , Piperazinas/administração & dosagem , Piperazinas/uso terapêutico , Purinas/administração & dosagem , Purinas/uso terapêutico , Citrato de Sildenafila , Esplenomegalia/etiologia , Esplenomegalia/radioterapia , Sulfonas/administração & dosagem , Sulfonas/uso terapêutico , Vasodilatadores/administração & dosagem , Vasodilatadores/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA